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Abstract We ascertained a nuclear family in which three of
four siblings were affected with an unclassified autosomal
recessive myopathy characterized by severe weakness, respi-
ratory impairment, scoliosis, joint contractures, and an unusual
combination of dystrophic and myopathic features on muscle
biopsy. Whole genome sequence from one affected subject
was filtered using linkage data and variant databases. A single
gene, MEGF10, contained nonsynonymous mutations that co-
segregated with the phenotype. Affected subjects were com-
pound heterozygous for missense mutations c.976T>C
(p.C326R) and c.2320T>C (p.C774R). Screening the
MEGF10 open reading frame in 190 patients with genetically
unexplained myopathies revealed a heterozygous mutation,
c.211C>T (p.R71W), in one additional subject with a similar
clinical and histological presentation as the discovery family.
All three mutations were absent from at least 645 genotyped
unaffected control subjects. MEGF10 contains 17 atypical
epidermal growth factor-like domains, each of which contains
eight cysteine residues that likely form disulfide bonds. Both
the p.C326R and p.C774R mutations alter one of these
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DOI 10.1007/s10048-012-0315-zresidues, which are completely conserved in vertebrates. Pre-
vious work showed that murine Megf10 is required for pre-
serving the undifferentiated, proliferative potential of satellite
cells, myogenic precursors that regenerate skeletal muscle in
response to injury or disease. Here, knockdown of megf10 in
zebrafish by four different morpholinos resulted in abnormal
phenotypes including unhatched eggs, curved tails, impaired
motility, and disorganized muscle tissue, corroborating the
pathogenicity of the human mutations. Our data establish the
importance of MEGF10 in human skeletal muscle and suggest
satellite cell dysfunction as a novel myopathic mechanism.
Keywords MEGF10.Wholegenomesequencing.Linkage
analysis.Congenitalmyopathy.Satellitecells.Cleftpalate
Introduction
Congenital myopathies result from a variety of genetic
defects [1] that manifest histologically as a disturbance in
the structure or organization of myofibers, evident on biopsy
by abnormalities such as minicores, central cores, central
nuclei, ragged red fibers, nemaline rods, or rimmed vacuoles
[2]. By contrast, muscular dystrophies are a class of
myopathy in which normally developed muscle tissue
undergoes destructive cycles of degeneration and regen-
eration, leading to distinct pathological hallmarks, including
replacement of muscle tissue with fat and infiltration of endo-
mysial connective tissue [3]. These features are usually absent
from congenital myopathies, and likewise, minicores and
other myopathic disruptions are typically absent from dystro-
phic muscle. Multiminicore disease (MmD) is an autosomal
recessive congenitalmyopathy characterized bypredominant-
ly axial and proximal muscle weakness, frequently in con-
junctionwithprogressive scoliosisand respiratory difficulties.
The defining histological feature is the presence in a large
proportion of muscle fibers of minicores, short regions of
sarcomeric disorganization with few or no mitochondria [4].
Mutations in the genes SEPN1 and RYR1 explain many but
not all cases of MmD [5–8].
The discovery of the genetic basis for such Mendelian
diseases has been facilitated by efficient genomewide se-
quencing methods, notably exome sequencing [9]a n dw h o l e
genome sequencing [10]. Although selective sequencing of
exons is currently cost-effective, sequencing of the entire
genomeofferstheopportunitytoidentifynon-exonic variants,
extract higher resolution information on copy number and
structural mutations, and potentially provide superior cover-
age of the exome than targeted capture methods achieve.
Regardless of the choice of technology, either multiple pro-
bands with a genetically homogeneous disease [11]o rl i n k a g e
data [12]are generally required to filter variantlistssufficiently
to implicate specific pathogenic mutations. Small families
previously considered inaccessible to conventional genetic
approaches can now be studied through a combination of
linkage analysis and genomewide sequencing.
Materials and methods
Written informed consent was obtained for all subjects for
participation in this study, which was approved by the
Institutional Review Board of Children's Hospital Boston
(CHB). Zebrafish experiments were conducted in compli-
ance with the guidelines of the CHB Institutional Animal
Care and Use Committee. Saliva or blood samples were
collected and genomic DNA was isolated. Muscle biopsy
slides were reviewed, and for subject 105-1, total RNA was
extracted from muscle tissue. All six members of family
1030 were genotyped at 10,204 single nucleotide polymor-
phisms (SNPs) using the GeneChip Human Mapping 10K
2.0 Xba Array (Affymetrix). Genomewide multipoint para-
metric linkage scans were performed using MERLIN v1.1.2
[13] with a recessive model, as described previously [14].
Whole genome sequencing and preliminary analysis (initial
mappings of reads, local de novo assembly, and variant
calling) were performed by Complete Genomics, Inc. using
a sequencing-by-ligation method with unchained reads [15].
Polymerase chain reaction (PCR) and Sanger sequencing
were performed according to standard protocols. Mutations
were genotyped in control subjects using Custom TaqMan
SNP Genotyping Assays (Applied Biosystems).
Four custom morpholinos (Gene Tools, LLC) were
designed against the intron 4–exon 5 (MO1), intron 5–exon
6( M O 2 ) ,e x o n8 –intron 8 (MO3), and exon 17–intron 17
(MO4) junctions. These morpholinos were intended to induce
skippingofthetargetedexons,homologoustohumanexons7,
8, 10, and 19. MO1 and MO2 were designed against the 3′
splice acceptor side of the intron, and a full exonic skip would
induce a frameshift and premature truncation of megf10,
whereas MO3 and MO4 were designed against the 5′ splice
donorsideoftheintron,andafullexonicskipwouldinducean
in-framedeletionoftheexonshomologoustothosemutatedin
family 1030. Zebrafish injections, birefringence assays, histo-
chemistry, and immunohistochemistry were performed as de-
scribed previously [16,17]. For electron microscopy (EM),
ultrathin sections were stained with uranyl acetate and lead
citrate and were observed with an FEI Tecnai Spirit at 80 kV.
Results
Case reports
We ascertained a non-consanguineous Caucasian family of
mixed European ancestry in which three of four siblings had
116 Neurogenetics (2012) 13:115–124an undiagnosed autosomal recessive myopathy, which resem-
bled MmD in some respects (Fig. 1 and Online Resource 1).
Affectedmembersoffamily1030presentedwithweaknessby
12 months of age, initially in the neck. Weakness was present
throughoutthe bodybut was primarily axial and proximaland
stabilized in adolescence. Facial weakness was also evident.
Contractures of the neck were observed in infancy, and con-
tractures of the elbows, knees, and heel cords developed by
adulthood. Serum creatine kinase (CK) levels measured prior
to age 10 years were mildly elevated. All three patients had
childhood onset scoliosis and were treated with spinal fusion
surgery, and beginning at age 10–11 years, they all developed
respiratory problems treated with bilevel positive airway pres-
sure ventilation at night. One of the patients had cleft palate at
birth that was surgically repaired, and a second had a midline
ridge on her palate in adulthood, while the palate of the third
patient appeared normal. All three affected siblings had
hypernasal speech, which was not observed in their un-
affected parents and sibling. Muscle biopsy tissue from
affected subjects showed replacement of myofibers with
fatty tissue, increased perimysial and endomysial connec-
tive tissue, and isolated regenerating fibers, features
found in muscular dystrophies (Fig. 2). However, moth-
eaten fibers and minicores were also observed, sugges-
tive of a congenital myopathy. Rimmed vacuoles, inclu-
sions, central cores, nemaline rods, and ragged red fibers
were absent. ATPase staining demonstrated that most
atrophic fibers were type I and most hypertrophic fibers
were type II, but large type I fibers were also observed.
Overall, there was a slight predominance of type I fibers,
and they showed a more pronounced variability in size than
type II fibers. Prior to any genetic testing, the diagnosis was
described as limb girdle muscular dystrophy or spinal muscu-
lar atrophy, but the symptoms were also consistent with the
clinical spectrum of a congenital myopathy or congenital
muscular dystrophy.
Subject 105-1 was a female Caucasian with distant Por-
tuguese ancestry, diagnosed with MmD. No one else in her
family was affected. At several weeks of age, she presented
with hypotonia, initially manifesting as a weak neck and
floppy head. A markedly high arched palate and failure to
thrive as a result of poor feeding were noted, as were blue-
tinged sclera and hyperflexible joints. She had frequent
acute episodes of pulmonary infection as a child but
reported no chronic breathing problems and breathed unas-
sisted at night. Serum CK level at age 10 years was mildly
elevated at 302 U/L (upper limit of reference range 105 U/L),
and mild scoliosis was reported at the same time, which
progressed to 20° by age 12 years. Throughout child-
hood, she continued to exhibit a mild, non-progressive,
primarily proximal weakness (including facial weakness),
as well as deficits in motor performance. Muscle biopsy
showed marked fiber size variation, internalized nuclei,
and slightly increased endomysial connective tissue, as
wellasprominent patches ofdecreased NADH activitywithin
myofibers, consistent with moth-eaten fibers or minicores
(Online Resource 2). Electron microscopy showed focal areas
of Z-band disarray devoid of mitochondria and extending
across a few sarcomeres in the longitudinal axis, confirming
the presence of minicores.
Fig. 1 Clinical symptoms of
an unclassified autosomal
recessive congenital myopathy.
a Three siblings from a non-
consanguineous nuclear family
(1030) presented with child-
hood weakness, respiratory
problems, and scoliosis.
b The arm in subject 1030-1
illustrated elbow contracture to
approximately 20°. Biceps and
triceps strength in subject
1030-1 were 3+/5 (Medical
Research Council scale). c The
necks of subjects 1030-1 and
d 1030-6 showed neck atrophy
and contractures, more
prominent in subject 1030-6.
Neck flexion strength was 2/5
in 1030-1 and 0/5 in 1030-6.
Neck extension strength was
normal in both subjects
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Family 1030 produced positive LOD scores at sixteen
genomic loci, ten of which approached the theoretical maxi-
mum LOD score of 1.329, and which collectively contained
over1,000 candidate genes (Online Resource 3).Both SEPN1
andRYR1 wereexcluded,aswereACTA1andTPM3,inwh ic h
mutations cause congenital fiber type disproportion [18,19], a
myopathy clinically similar to MmD. The linkage intervals
included the myopathy genes MYOT and CRYAB [1], but
neither of these contained coding or splice site mutations by
Sanger sequencing.
Whole genome sequencing and mutation analysis
Whole genome sequencing of one affected subject from fam-
ily 1030 yielded a mean coverage depth of 74-fold, with
95.9% of the genome fully called (Online Resource 4). We
screened all 16 linked regions for genes containing either
homozygous or compound heterozygous variants that altered
the amino acid sequence or consensus splice site sequence of
an encoded protein. Four linked genes contained putative
compound heterozygous, nonsynonymous mutations absent
from dbSNP v131. Sanger sequence analysis of three called
variants in ZNF99 showed that all three were homozygous for
the reference sequence in all family members; ZNF99 is a
highly repetitive gene and the variant calls may have been
due to misaligned reads. Mutations in LOC100128682 and
LAMA5 were likewise excluded, as they failed to segregate
with the phenotype in the entire family. By contrast, the het-
erozygous missense mutations c.976T>C (p.C326R) and
c.2320T>C (p.C774R) in MEGF10, the sole remaining can-
didate, were confirmed by Sanger sequencing to be in trans in
affected subjects and to segregate with the myopathy in all six
family members.
MEGF10 lies within a linkage peak on chromosome 5
that reached the maximum possible LOD score of 1.329.
Both mutations were absent from dbSNP v135, 1,000
Genomes Project data (May 2011 release, 1,094 samples)
[20], 5,379 samples from the NHLBI Exome Sequencing
Project (ESP) [21] and 56 internal non-myopathy genomes
also sequenced at Complete Genomics, Inc. The c.976T>C
and c.2320T>C mutations were alsoabsentfrom715 and 645
genotyped unaffected control subjects, respectively (Table 1).
The p.C326 and p.C774 positions are both completely con-
servedin43species.Inaccordancewiththelinkagedata,there
werenononsynonymousmutationsinSEPN1,RYR1,ACTA1,
or TPM3. Moreover, none of the more than 70 other genes
Fig. 2 Dystrophic and myopathic pathology in family 1030 muscle
biopsy.aHematoxylin and eosin (H&E) staining of sectioned muscle
biopsy tissue taken from the left biceps of female subject 1030-1 at age
8 years showed rounded fibers with markedly excessive variation in fiber
diameter, fatty replacement, and increased internalized nuclei. Some of the
large, hypertrophic fibers were 150 μm in diameter. Inflammation and
necrosis were not observed, but scattered basophilic regenerating fibers
were present. Magnification is ×10; scale bar is 200 μm. b Modified
Gomori trichrome staining of 1030-1 biceps highlighted the increased
endomysial connective tissue, as well as a single focus of myonecrosis
(arrow). Magnification is ×20; scale bar is 100 μm. c NADH reductase
histochemistry of 1030-1 biceps showed many fibers with scattered clear-
ings or “moth-eaten” appearance, reflecting disruption of the myofibril by
minicores (arrows), predominantly in the darker type I fibers. Magnifica-
tion is ×40; scale bar is 50 μm. d H&E staining of muscle biopsy tissue
taken from the right thigh of female subject 1030-4 at age 9 years showed
clusters of polygonal myofibers with abundant fatty replacement. There
was excessivevariationinfiberdiameterwithfrequenthypertrophicfibers,
75–95 μm in diameter. Degeneration, necrosis, or basophilic regenerating
fibers were not seen. Magnification is ×20; scale bar is 100 μm
118 Neurogenetics (2012) 13:115–124previouslyimplicatedinmusculardystrophies,myopathies,or
spinal muscular atrophies [1] contained a homozygous or
more than one heterozygous nonsynonymous mutation, once
variants in dbSNP v131, 1,000 Genomes, or 56 internal
genomes were discarded.
BySangersequencing,wescreenedtheentireopenreading
frameofMEGF10in190additionalpatientswithunexplained
myopathies, as well as selected exons in another 82 patients.
One subject was identified with only a single demon-
strable heterozygous mutation; subject 105-1 carried a
novel c.211C>T (p.R71W) mutation that was absent
from dbSNP v135, 1,000 Genomes data, ESP data, 56
internal genomes, and 699 genotyped unaffected control
subjects. The p.R71 residue is conserved in 39 of 41
species (two species of fish having different hydrophilic
residues, in contrast to the hydrophobic mutant residue
tryptophan). The c.211C>T mutation was heterozygous in
an unaffected parent of subject 105-1, so it was not de novo
dominant. Sanger sequencing further revealed that the subject
had no coding or splice site mutations in SEPN1 or RYR1.T o
search for a second recessive mutation in MEGF10,w es e -
quenced its entire open-reading frame in reverse-transcriptase
PCR (RT-PCR) amplicons derived from skeletal muscle RNA.
Expression of both alleles at the c.211C>T site in exon 4 was
verified by amplification and sequencing of full-length cDNA.
However, we did not identify a heterozygous exonic copy
number change, inversion, or other structural mutation. Never-
theless, because the p.R71W mutation is a nonconservative
substitution not found in control subjects, there were no non-
synonymous mutations in SEPN1 or RYR1 in this patient, and
the clinicalandhistological characteristics were similar tothose
of family 1030 patients, subject 105-1 may carry a second
mutation in MEGF10 that we were unable to detect.
Knockdown of megf10 in zebrafish
To provide additional evidence for the pathogenicity of
MEGF10 mutations, we knocked down expression of full-
length zebrafish megf10 using four antisense splice-
blocking morpholino oligonucleotides (MOs), referred to
as MOs 1, 2, 3, and 4 (Online Resource 5). We compared
the morphant phenotypes induced by injection of these MOs
to uninjected, wild-type fish and fish injected with a
standard control morpholino (COMO). The ability of the four
MOstoblocksplicingwasverifiedbyperformingRT-PCRon
total RNA harvested from treated zebrafish (Online Resource
6). All MOs induced the formation of mis-spliced products to
some extent, but they generally produced multiple bands not
necessarily corresponding in size to the amplicon predicted to
result from full skipping of the targeted exon.
Anti-megf10 morpholinos resulted in several phenotypes at
4 days post-fertilization, generally including curled or bent tails,
impaired swimming behavior, and diminished motility in re-
sponse to touch, all consistent with a myopathy (Fig. 3a, Online
Resources 7–14). In approximate proportion to dose, MO1-
treated fish showed tails bent at the tip and defective swimming.
The phenotypes induced by MO2 were the most severe; up to
6n go fm o r p h o l i n oc a u s e ds e v e r e l yc u r l e dt a i l s ,s m a l lh e a d s ,
ineffective swimming, or unhatched eggs, and at the highest
dose of 12 ng, MO2 was lethal. In contrast, 6 ng of MO3 and
MO4 produced only a few affected fish out of more than 40
injected, but at 12 ng, both morpholinos produced curved tails,
abnormal swimming, and unhatched eggs. Thus, at different
doses, all four MOs caused the same basic morphological and
motility defects. A single fish in each of the COMO groups
showed a mildly curved tail, and two of these fish also had an
inflated yolk sac or bloated appearance, which are consistent
with injection trauma. Otherwise, neither wild-type nor COMO-
treated fish exhibited any phenotypes suggestive of a myopathy.
In morphant fish with severely curled tails, particularly
those treated with MO2, the organization of muscle tissue
was irregular, with the tail somites showing a less distinct
V-shaped chevron pattern than control fish (Fig. 3b). This
apparent muscle defect was further investigated using bire-
fringence, the ability of highly organized sarcomeres to
rotate polarized light, which can be used to assess muscle
integrity [22]. Fish treated with 6 ng of MO1 showed a
reduction in birefringence, and 6 ng of MO2 induced a more
dramatic decrease in birefringence that corresponded in its
location to the disruption of somite structure evident by
brightfield microscopy. The abnormal tail morphology and
reduced birefringenceinmegf10morphantsclosely resembled
the phenotypes of morphant fish with deficits in known mus-
cular dystrophy gene orthologs [16,23–25].
To further test whether megf10 morphant phenotypes
reflected a disruption of myofiber integrity, we performed
Table 1 Missense mutations in MEGF10 in congenital myopathy patients
Mutation Amino acid
substitution
Family Exon Domain Conservation Total controls
genotyped
Controls with
European ancestry
c.211C>T p.R71W 105 4 Emilin 39/41 species 699 261
c.976T>C p.C326R 1030 10 EGF-like 6 43/43 species 715 257
c.2320T>C p.C774R 1030 19 EGF-like 16 43/43 species 645 250
All mutations were heterozygous in affected subjects and absent from all genotyped controls
Neurogenetics (2012) 13:115–124 119immunohistochemical staining of whole fish with antibodies
against β-dystroglycan, a sarcolemmal protein, and myosin
heavy chain, a sarcomeric protein. MO1 treatment produced
subtle abnormalities in somite shape and abundant gaps
between myofibers, while MO2 resulted in a similar but
more pronounced disturbance of muscle organization
(Fig. 4). The sarcolemmal proteins dystrophin and laminin
were also tested and gave similar results as β-dystroglycan
(data not shown). To investigate these anomalies in greater
detail, we performed toluidine blue staining and EM, which
demonstrated that compared to COMO-treated zebrafish,
MO2-treated zebrafish muscle showed widespread myofibril-
lar disorganization and decreased striation (Online Resource
15). These structural defects suggest that the motor impair-
mentsofmorphantfishweredueatleastinparttoamyopathic
process, as opposed to a neuropathy.
Discussion
MEGF10 encodes multiple epidermal growth factor (EGF)-
like domains 10 (MEGF10), which contains 17 atypical
Fig. 3 Morphological and birefringence abnormalities in megf10 mor-
phant zebrafish. a Zebrafish treated with anti-megf10 morpholinos
were more likely to die or exhibit an abnormal phenotype than control
fish. Abnormal phenotypes were defined as bent or severely curled
tails, unhatched eggs, or impaired swimming, including unproductive
quivering, rotating in circles, or reduced motility in response to touch.
Total numbers of fish examined in each category are given in paren-
theses after the treatment group label. The remainder of fish in each
category appeared unaffected or had non-specific phenotypes, which
included four COMO-treated fish (one at each dose) with a slightly
curled tail, inflated yolk sac, or bloated appearance, and six fish treated
with 6 ng of MO3 that had inflated precardia. b Rows from top to
bottom are wild-type, 6 ng COMO, 6 ng MO1, and 6 ng MO2.
Columns from left to right are brightfield ×5 magnification, birefrin-
gence ×5 magnification, brightfield ×11.25 magnification, and bire-
fringence ×11.25 magnification. Compared to control fish, MO1-
treated fish showed decreased birefringence, and MO2-treated fish
had marked disruption of somite boundaries, a thinner tail with less
muscle tissue overall, and substantially decreased birefringence
120 Neurogenetics (2012) 13:115–124EGF-like domains, each with eight cysteine residues [26].
The p.C326R and p.C774R mutations substitute the fourth
and sixth cysteines of EGF-like domains six and sixteen,
respectively, for arginines. All eight cysteines in other pro-
teins containing eight-cysteine atypical EGF-like domains
form disulfide bridges [27], indicating the mutations in
family 1030 likely disrupt MEGF10 protein structure. Sim-
ilarly, the p.R71W mutation in subject 105-1 is a noncon-
servative substitution within the emilin domain, which may
function in protein–protein interactions [28]. All three muta-
tions were predicted by PolyPhen [29]t ob e“probably
damaging”, and the two cysteine substitutions were pre-
dicted to disrupt annotated disulfide bond sites, as expected.
Nonsense and frameshift mutations in MEGF10 were
recently determined to be the cause of a severe congenital
myopathy with diaphragmatic weakness, areflexia, and dys-
phagia. One reported family was compound heterozygous
for the c.2320T>C (p.C774R) missense mutation we iden-
tified in family 1030 and a frameshift mutation [30]. The
phenotypes described therein are generally similar to those
of families 1030 and 105, but are more severe. This differ-
ence is consistent with the total loss of detectable MEGF10
expression observed in the reported families, compared to
the expected misfolding of MEGF10 protein due to disrup-
tion of disulfide bonds in family 1030. Accordingly, affect-
ed members of family 1030 may retain a small amount of
residual MEGF10 function, though genetic background or
other factors could also account for clinical heterogeneity
between families. Moreover, minicores were not noted in
the biopsies from the reported families with null mutations
[30,31] but were a prominent feature in our patients with
missense mutations. Unstructured minicores in MmD may
result from primary defects affecting intracellular redox
state or regulation of excitation–contraction coupling at the
triad [32]. The molecular mechanisms by which SEPN1 and
RYR1 mutations result in minicores in MmD have not been
elucidated, and likewise, the relationship between MEGF10
mutations and minicore formation is unclear. Further char-
acterization is required to determine the effect of missense
mutations on MEGF10 protein function and sarcomeric
structure and to investigate whether MEGF10 shares a func-
tional pathway with SEPN1 or RYR1.
H u m a nM E G F 1 0o rm o u s eM e g f 1 0p r o t e i nh a sb e e n
described as an engulfment receptor expressed in the brain
[33–35] and involved in phagocytosis of apoptotic neuronal
corpses [36]. One of the patients in family 1030 had overt
Fig. 4 Myopathic features of
megf10 morphant zebrafish
muscle. Immunohistochemistry
was performed with antibodies
against β-dystroglycan (left)a n d
myosin heavy chain (right)o n
wild-type fish and morphants
treated with 6 ng COMO, 6 ng
MO1, and 6 ng MO2 (top to
bottom). Wild-type and COMO-
treated fish showed myosepta
with straight boundaries and
tightly packed myofibers.
Compared to control fish,
MO1-treated fish showed subtle
curving of myosepta and loosely
packed myofibers with occa-
sional prominent gaps (arrow),
and MO2-treated fish showed
less distinct somite boundaries
and abundant gaps between
myofibers (e.g., in somites
indicated by arrows), creating
an overall disorganization of
the fiber pattern
Neurogenetics (2012) 13:115–124 121cleft palate at birth, while a second patient had a midline
ridge on her palate and a tendency to reflux liquids into her
nose. All three affected subjects had hypernasal speech,
which can be a sign of submucous cleft palate [37]. Subject
105-1 had a high-arched palate and poor feeding as an
infant. Of seven patients in four reported families with
congenital myopathy and mutations in MEGF10, one pa-
tient had cleft palate and an additional three patients had
high-arched palate [30]. Although these clinical features are
relatively nonspecific, occurring commonly in patients with
myopathic facies, the expression of mouse Megf10 in brain
[35,38] is consistent with a role in craniofacial development.
In addition, Megf10 interacts with Ap2m1, one of four sub-
units of the assembly protein complex 2 (AP2) [35]. Ablation
of Ap2b1, which encodes another of the AP2 subunits, causes
cleft palate in mouse [39]. Furthermore, Megf10 in muscle is
onlyexpressedincells that alsoexpressPax7[38],andPax7
−/−
null mice exhibit facial malformations of the maxilla and nose
due to a defect in cephalic neural crest development [40].
Lastly, some morphant zebrafish treated with MO1 or MO2
showedsmallheadsrelativetocontrolfish,furthersuggestinga
possible role for megf10 in head development. Collectively,
these data indicate that MEGF10 may influence palate forma-
tion or facial midline determination in humans, but more
research is required to test this hypothesis.
In addition to brain, mouse Megf10 is expressed in mus-
cle satellite cells [38,41], a population of committed, myo-
genic precursors that specifically express the transcription
factor Pax7 and contribute to the regeneration of adult
muscle in response to exercise, disease, or injury [42,43].
The importance of satellite cell function in mouse muscle
maintenance has been demonstrated; Pax7
−/− mice have a
reduced number of satellite cells as embryos and very few or
none as adults, and muscle regeneration is impaired in these
mice [44]. Recent studies further confirmed that Pax7
+
satellite cells are completely required for muscle regenera-
tion [45–47], suggesting that in humans, compromised sat-
ellite cell function could result in a myopathic phenotype.
Expression of Megf10 in skeletal muscle is restricted to
satellite cells and is low in resting muscle but increases
dramatically in regenerating muscle upon activation of
satellite cells by treatment with cardiotoxin [38]. Megf10
regulates the differentiation program in skeletal myoblasts,
as overexpression of Megf10 in C2C12 myoblasts increases
proliferation and decreases differentiation, whereas knock-
down of Megf10 in primary myoblasts and individual myo-
fibers causes precocious differentiation and a reduction of
activated satellite cells [38].
Consistent with the role of Megf10 in mouse myoblasts,
our data establish that human MEGF10 is required for
normal muscle function. Due to presumed disruption of
disulfide bonds, the p.C326R and p.C774R mutations in
family 1030 likely result in a loss of MEGF10 function, in
which case we hypothesize that excessive differentiation of
satellite cells could deplete the population of self-renewing
cells available to regenerate damaged muscle fibers. Such
impairment could potentially explain the dystrophic features
observed in patient biopsy tissue at ages 8 and 9. Notably, a
recent study found that Sepn1
−/− null mice showed a de-
crease in the baseline number of satellite cells in adult
skeletal muscle, as well as imperfect muscle regeneration
in response to a first injury and an inability to regenerate
muscle following a second injury. MmD patients with
SEPN1 deficiency also had a reduction in their satellite cell
population [48]. These data suggest that both MmD and the
myopathy described here, which share some clinical and
histological characteristics, may arise through a common
pathogenic mechanism of satellite cell dysfunction.
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